RABAC1: A Potential Drug Target and Biomarker for Pain Management

Target Name: RABAC1

NCBI ID: G10567

RABAC1

RABAC1: A Potential Drug Target and Biomarker for Pain Management

Abstract:

RABAC1, or Prenylated Rab acceptor protein 1, is a protein that has been identified as a potential drug target and biomarker for pain management. Its role in pain signaling and its potential as a drug target make it an attractive target for researchers to investigate. This article will discuss the structure and function of RABAC1, its role in pain signaling and its potential as a drug target, and current research efforts to target RABAC1.

Introduction:

Pain is a natural response to tissue damage or injury and can be a highly unpleasant experience for patients. Chronic pain can significantly impact a person's quality of life and overall well-being. The pain signaling pathway is complex and involves multiple molecules, including G protein -coupled receptors (GPCRs) and ion channels. RABAC1, a protein that has been identified as a potential drug target and biomarker for pain management, is a key player in this pathway.

Structure and Function:

RABAC1 is a 21-kDa protein that is expressed in various tissues, including brain, spinal cord, and peripheral tissues. It is a member of the Rab gene family, which is known for the production of proteins involved in synaptic transmission. RABAC1 is characterized by a long N-terminus, a unique disulfide bond, and a N-glycosylation site.

RABAC1 is involved in pain signaling by modulating the activity of GPCRs. GPCRs are a family of transmembrane proteins that play a central role in sensory signaling, including pain perception. GPCRs are composed of an extracellular portion, a transmembrane region, and an intracellular portion. The transmembrane region of GPCRs contains the receptor protein, which is involved in the formation of the receptor-ligand complex, and the intracellular portion, which contains the co-factor proteins that help to modulate the activity of the receptor.

RABAC1 is known to modulate the activity of several GPCRs, including TrkA, TrkB, and TrkC. TrkA and TrkB are involved in the perception of pain, while TrkC is involved in the regulation of pain modulation. RABAC1 has been shown to interact with TrkA and TrkC and to modulate their activity. These interactions suggest that RABAC1 may play a role in the modulation of pain perception.

In addition to its role in modulating pain perception, RABAC1 has also been shown to be involved in pain modulation by modulating the activity of GPRs. GPRs are a family of nuclear receptors that play a central role in mediating pain signaling. GPRs are composed of a transmembrane region, an intracellular portion, and an extracellular portion. The transmembrane region of GPRs contains the receptor protein, which is involved in the formation of the receptor-ligand complex, and the intracellular portion, which contains the co-factor proteins that help to modulate the activity of the receptor.

RABAC1 has been shown to interact with GPRs and to modulate their activity. These interactions suggest that RABAC1 may play a role in the modulation of pain modulation by GPRs.

Potential Drug Target:

The potential drug target for RABAC1 is its role in pain signaling and its involvement in the modulation of GPCRs and GPRs. RABAC1 has been shown to play a role in the modulation of pain perception and has been shown to interact with TrkA and TrkC, which are involved in the perception of pain. Additionally, RABAC1 has been shown to interact with GPRs, which are involved in

Protein Name: Rab Acceptor 1

Functions: General Rab protein regulator required for vesicle formation from the Golgi complex. May control vesicle docking and fusion by mediating the action of Rab GTPases to the SNARE complexes. In addition it inhibits the removal of Rab GTPases from the membrane by GDI

The "RABAC1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RABAC1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets